LEADER 04156nam  22005295  450 
001 9910337938103321
005 20200705055415.0
010   $a3-030-05542-6
024 7 $a10.1007/978-3-030-05542-4
035   $a(CKB)4100000007656740
035   $a(DE-He213)978-3-030-05542-4
035   $a(MiAaPQ)EBC5702850
035   $a(PPN)23500751X
035   $a(EXLCZ)994100000007656740
100   $a20190212d2019      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aReviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders /$fedited by Paul C. Guest
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (XIII, 328 p. 28 illus., 26 illus. in color.) 
225 1 $aProteomics, Metabolomics, Interactomics and Systems Biology,$x2730-6216 ;$v1118
311   $a3-030-05541-8 
327   $a1. The Potential of ?Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer?s Disease in African Americans -- 2. The Role of Biomarkers in Alzheimer?s Disease Drug Development -- 3. Mitochondrial Involvement in Mental Disorders; Energy Metabolism, Genetic and Environmental Factors -- 4. Lymphocytes, Platelets, Erythrocytes and Exosomes as Possible Biomarkers for Alzheimer's Disease Clinical Diagnosis -- 5. Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms -- 6. Neuroimaging Studies of Cognitive Function in Schizophrenia -- 7. The Role of Biomarkers in Psychiatry -- 8. Interactome Studies of Psychiatric Disorders -- 9. MicroRNAs in Major Depressive Disorder -- 10. Proteomic Markers for Depression -- 11. Advances in Biomarker Studies in Autism Spectrum Disorders -- 12. Proteomic Investigations of Autism Spectrum Disorder: Past Findings, Current Challenges and Future Prospects -- 13. Role of the Gut Microbiome in Autism Spectrum Disorders -- 14. Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia -- 15. Early Detection and Treatment of Patients with Alzheimer?s Disease: Future Perspectives.
330   $aThis book includes a series of reviews on general aspects of biomarker use in the study of psychiatric and neurodegenerative diseases and the development of medications involved in their treatment. It describes the pros and cons of the various approaches and covers the successes and failures in this research field. It is only by a thorough understanding of the shortcomings that progress can be made. The overall goal is to facilitate the understanding and treatment of these disorders, by providing a viable mechanism of catching up with other areas of modern medicine, such as diabetes and heart disease. Finally, it is anticipated that the development and application of valid biomarker tests and the leveraging of novel drug targets will help the fields of psychiatry on neurodegenerative disorders move into the area of personalized medicine where the right patients can receive the right medication at the right time for the best possible outcome.
410  0$aProteomics, Metabolomics, Interactomics and Systems Biology,$x2730-6216 ;$v1118
606   $aSystems biology
606   $aProteomics
606   $aGene expression
606   $aSystems Biology$3https://scigraph.springernature.com/ontologies/product-market-codes/L15010
606   $aProteomics$3https://scigraph.springernature.com/ontologies/product-market-codes/L1403X
606   $aGene Expression$3https://scigraph.springernature.com/ontologies/product-market-codes/B12010
615  0$aSystems biology.
615  0$aProteomics.
615  0$aGene expression.
615 14$aSystems Biology.
615 24$aProteomics.
615 24$aGene Expression.
676   $a570
702   $aGuest$b Paul C$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910337938103321
996   $aReviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders$92079125
997   $aUNINA